ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection

Trial Profile

ECOSPOR: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium Difficile Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs SER 109 (Primary)
  • Indications Clostridium infections
  • Focus Therapeutic Use
  • Acronyms ECOSPOR
  • Sponsors Seres Therapeutics
  • Most Recent Events

    • 04 May 2017 According to Seres Therapeutics media release, data from this study was presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting.
    • 25 Apr 2017 Results presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases
    • 31 Jan 2017 Results from this and an open label extension study published in a Seres Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top